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Introduction
Overactive bladder (OAB) is a prevalent and distress-
ing syndrome characterised by urinary urgency, with
or without urgency incontinence, usually with
increased daytime frequency and nocturia (1,2). Esti-
mates suggest that 16.5% of adults in the United
States, including 16.0% of men and 16.9% of
women, have OAB (3). Similarly, OAB affects 16.6%
of adults in Europe, including 15.6% of men and
17.4% of women (4). It is well established that the
prevalence of OAB increases with age, as does the
likelihood of experiencing urgency urinary inconti-
nence (UUI) (3,4). In Europe, the prevalence of
OAB in men and women has been estimated to be
3.4% and 8.7% among those 40–44 years of age,
18.9% and 16.9% in those 60–64 years of age and
41.9% and 31.3% in subjects ‡ 75 years of age
respectively (4). A US-based study yielded similar
age-related increases in OAB prevalence rates (3).
Thus, the number of individuals affected by OAB is
expected to increase because the older population is
growing in the United States (5) and worldwide (6).
Overactive bladder imposes a considerable eco-
nomic burden on society (7–10) and is associated
with reduced health-related quality of life (HRQL)
(11,12), as well as several comorbidities, such as
depression (8,13), urinary tract infections (UTIs)
(7,8,10) and falls⁄fractures (8,10). Older individuals
may be particularly vulnerable to these comorbidi-
ties; however, the available evidence suggests that
most older people with urinary incontinence do not
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controlled trials. Subjects with OAB symptoms, including urinary frequency and
urgency (and nocturia in two studies) with or without urgency urinary incontinence,
received qd treatment with tolterodine ER (4 mg) or placebo for 8–12 weeks. Data
were stratiﬁed post hoc by age group: < 65 (n = 2531), 65–74 (n = 1059) and
‡ 75 years (n = 573). Tolerability was assessed by evaluating the occurrence of
adverse events (AEs). AE occurrences from each study were mapped to the Med-
DRA coding dictionary of preferred terms. Results: Discontinuation rates were
slightly higher among subjects ‡ 75 years of age vs. those < 65 years of age;
however, this was observed in subjects treated with placebo as well as tolterodine
ER. Overall, there were no signiﬁcant differences in the occurrence of dry mouth,
headache, constipation, nausea, urinary tract infection, blurred vision, dry eye,
dizziness and micturition disorder in older (65–74 or ‡ 75 years) vs. younger
(< 65 years) subjects treated with tolterodine ER relative to placebo (treat-
ment · age; all p > 0.1). Dry mouth was the only AE consistently associated
with tolterodine ER treatment (< 65 years, 17%; 65–74 years, 16%; ‡ 75 years,
15%). The occurrence of all other AEs was £ 5% in most age and treat-
ment cohorts. Most AEs were mild or moderate in all age and treatment cohorts.
Conclusion: The nature and frequency of AEs associated with tolterodine ER
treatment were similar across age groups in subjects with OAB, suggesting that
tolterodine ER was not associated with an increased risk of AEs in older vs. youn-
ger subjects and, thus, is a suitable ﬁrst-line pharmacotherapy treatment for OAB
in this population.
What’s known
• Overactive bladder (OAB) is a prevalent and
distressing syndrome characterised by urinary
urgency, with or without urgency urinary
incontinence, usually with increased daytime
frequency and nocturia.
• OAB is associated with reduced health-related
quality of life (HRQL) and related comorbidities,
which may be more prevalent in the older
population.
What’s new
This retrospective analysis of pooled data from ﬁve
large placebo-controlled clinical trials of patients
with OAB examined the tolerability proﬁle of
tolterodine extended release in subjects aged
65–74 and ‡ 75 years compared with those aged
< 65 years.
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availability of effective therapies.
Antimuscarinic agents, such as tolterodine, are
currently the mainstay pharmacotherapy for OAB.
Tolterodine is believed to work by reducing involun-
tary detrusor contractions (16,17) and has been
shown to improve OAB symptoms (18–23) and the
HRQL of individuals with OAB (24,25). Several stud-
ies have demonstrated that tolterodine is effective for
the treatment of OAB symptoms speciﬁcally in older
subjects (23,26–28). Antimuscarinics are generally
well tolerated but are associated with certain adverse
events (AEs), including dry mouth, blurred vision,
constipation and dyspepsia (29).
Older individuals have special issues related to the
tolerability of pharmacotherapeutic agents, such as
increased comorbidities, polypharmacy and higher
vulnerability to AEs. With the ageing demographical
proﬁle of the United States, it is important to under-
stand whether the older patient may be at increased
risk for AEs associated with antimuscarinic therapy
for this condition. To that end, we investigated the
tolerability proﬁle of tolterodine extended release
(ER) in subjects aged 65–74 years and ‡ 75 years
with OAB relative to those aged < 65 years using
pooled data from ﬁve large placebo-controlled clini-
cal trials.
Methods
In previously published reports examining the efﬁ-
cacy and tolerability of tolterodine in older subjects,
the most commonly reported AEs were dry mouth,
headache and constipation (23,26,27). For this retro-
spective evaluation, data from ﬁve large, randomised,
double-blind, placebo-controlled clinical trials were
pooled because of similarity in study design, inclu-
sion⁄exclusion criteria and the enrolment of a large
number of subjects. All subjects were enrolled for the
treatment of OAB and received either placebo or tol-
terodine ER 4 mg qd. Participants were stratiﬁed
into three age cohorts to assess the occurrence of
commonly reported AEs and discontinuation rates.
Subjects aged ‡ 65 years were separated from those
aged < 65 years based on the deﬁnition of an ‘older’
person set forth in the Beers criteria (30). Addition-
ally, subjects aged ‡ 65 years were stratiﬁed into
65- to 74-year and ‡ 75-year cohorts to investigate
tolterodine ER tolerability in different age groups
among older subjects. Existing studies using a 65-year
age threshold to examine the efﬁcacy of OAB treat-
ment in older subjects have been criticised based on
the concern that this age is no longer representative
of the older population, and it has been suggested
that more data on drug tolerability in individuals
aged ‡ 75 years are needed (30). Primary results from
three of the ﬁve studies (Pﬁzer-sponsored studies
007, 027 and 037) have been published (19,22,31);
the results of the other two studies are publicly
available at http://www.clinicalstudyresults.org.
Urinary frequency (‡ 8 micturitions per day) and
urgency and⁄or UUI (‡ 5 episodes per week) were
key inclusion criteria in each trial. Trial durations
ranged from 8 to 12 weeks, and each trial was con-
ducted in full accordance with the Declaration of
Helsinki and International Conference on Harmoni-
sation guideline and principles of Good Clinical
Practice. The study protocol and all amendments for
each trial were approved by the appropriate Institu-
tional Review Boards and⁄or Independent Ethics
Committees at each centre. All subjects in each trial
provided written informed consent before entering
the study.
The speciﬁc AEs examined in the current analysis
included dry mouth, headache, constipation, nausea,
UTI, blurred vision, dry eye, dizziness and micturi-
tion disorder. The data reﬂect all reported AEs,
including those deemed related and unrelated to the
study drug. All AEs spontaneously reported by the
patient, directly observed by a clinician, or ascer-
tained through direct questioning of the patient were
included. Speciﬁc measurements of cognitive func-
tion were not conducted in any of these ﬁve individ-
ual trials. A logistic regression model was used to
determine whether the estimated treatment effect
(i.e. the difference between tolterodine ER and pla-
cebo) differed among the three age groups. The
alpha level was set at 0.10, and Wald chi-squares for
the treatment · age interaction terms are reported
for each AE.
Results
The characteristics of the study designs and subjects
for the ﬁve trials are shown in Tables 1 and 2 respec-
tively.
Discontinuation rates
There was a trend for subjects ‡ 75 years of age to
discontinue from the trials at a higher rate compared
with subjects < 65 years of age (Table 2). However,
this trend was observed in both tolterodine ER and
placebo arms; discontinuation rates among subjects
receiving tolterodine ER vs. placebo were 9% vs.
11% in subjects aged < 65 years, 8% vs. 10% in sub-
jects aged 65 to 74 years and 12% vs. 15% in sub-
jects aged ‡ 75 years respectively. The rates of
discontinuation because of AEs were similar for both
tolterodine ER and placebo groups (£ 5%) and in all
age categories, and there was no evidence of an
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Clinical trial number
Study 007 (N = 1012) Study 027 (N = 854) Study 037 (N = 850) Study 041 (N = 848) Study 047 (N = 596)
Inclusion
criteria
Frequency* and UUI Frequency* urgency
with or without UUI
and SUI
Frequency*, urgency and
nocturia, with or
without UUI
Frequency*, urgency and
nocturia, with or without
UUI
Frequency* and urgency
with or without UUI
Exclusion
criteria
SUI
Total urinary volume > 3 l⁄day
Signiﬁcant hepatic or renal
disease
UTI (symptomatic or recurrent)
Interstitial cystitis, haematuria,
or BOO
Recent electrostimulation or
bladder training therapy
Indwelling catheter or
intermittent
self-catheterisation
Pregnancy, lactation, or failure
by women of childbearing age
to use reliable contraception
Use of CYP3A4 inhibitors
Treatment within 2 weeks of
study with OAB therapy
or anticholinergic drugs
Total urinary volume
>3l⁄day
Signiﬁcant hepatic or
renal disease
UTI (symptomatic or
recurrent)
Interstitial cystitis,
haematuria, or BOO
Pregnancy, lactation,
or failure by women
of childbearing age to
use reliable
contraception
Use of CYP3A4
inhibitors
Non-surgical treatment
for incontinence within
4 weeks of study
Incontinence treatment
within 2 weeks of study
SUI
PVR > 200 ml
Qmax <1 0m l⁄s
Total urinary volume > 3 l⁄day
Signiﬁcant hepatic or renal
disease
UTI (symptomatic or recurrent)
Interstitial cystitis, haematuria
Recent electrostimulation or
bladder training therapy
Indwelling catheter or
intermittent
self-catheterisation
Pregnancy, lactation, or failure
by women of childbearing age
to use reliable contraception
Use of CYP3A4 inhibitors
Treatment within 2 weeks of
study with OAB therapy or
anticholinergic drugs
SUI
PVR > 200 ml
Qmax <1 0m l⁄s
Total urinary volume > 3 l⁄day
Signiﬁcant hepatic or renal
disease
UTI (symptomatic or recurrent)
Interstitial cystitis or haematuria
Recent electrostimulation or
bladder training therapy
Indwelling catheter or
intermittent
self-catheterisation
Pregnancy, lactation, or failure
by women of childbearing age
to use reliable contraception
Use of CYP3A4 inhibitors
Treatment within 2 weeks of
study with OAB therapy or
anticholinergic drugs
SUI
Interstitial cystitis or
BOO
UTI during run-in period
Recent
electrostimulation or
bladder training
therapy
Pregnancy, lactation, or
failure by women of
childbearing age to
use reliable
contraception
Allergy to tolterodine
Use of CYP3A4
inhibitors
Treatment within
2 weeks of study with
OAB therapy or
anticholinergic drugs
BOO, bladder outlet obstruction; CYP, cytochrome P450; OAB, overactive bladder; PVR, postvoid residual volume; Qmax, maximal ﬂow volume; SUI, stress urinary
incontinence; UTI, urinary tract infection; UUI, urgency urinary incontinence.*Deﬁned as ‡ 8 micturitions per day. Deﬁned as ‡ 5 episodes per week.
Table 2 Subject characteristics
Placebo TOL ER
< 65 years
(n = 1171)
65–74 years
(n = 477)
‡ 75 years
(n = 288)
< 65 years
(n = 1360)
65–74 years
(n = 582)
‡ 75 years
(n = 285)
Discontinuations, n (%)
Total* 126 (11) 49 (10) 43 (15) 115 (9) 45 (8) 35 (12)
Owing to an AE* 37 (3) 22 (5) 16 (6) 33 (2) 14 (2) 14 (5)
Men, n (%) 265 (23) 168 (35) 118 (41) 259 (19) 180 (31) 93 (33)
Mean (SD) age, years 50.8 (9.9) 69.0 (2.8) 79.1 (4.0) 50.7 (10.1) 69.1 (2.8) 78.9 (3.4)
Range 19–64 65–74 75–93 18–64 65–74 75–90
Race, n (%)
White 1034 (88) 452 (95) 278 (97) 1224 (90) 555 (95) 278 (98)
Black 73 (6) 15 (3) 6 (2) 71 (5) 13 (2) 4 (1)
Asian 17 (2) 4 (1) 1 (< 1) 18 (1) 4 (1) 2 (1)
Other 47 (4) 6 (1) 3 (1) 47 (3) 10 (2) 1 (< 1)
Mean (SD) body mass index, kg⁄m
2 29.1 (6.9) 29.0 (5.9) 26.6 (4.5) 29.1 (9.0) 28.9 (5.7) 27.7 (12.4)
Range 15.1–63.9 16.8–49.9 15.7–47.2 16.5–211.5 17.1–60.3 15.8–198.8
TOL ER, tolterodine extended release; AE, adverse event; *Discontinuations and AEs include those related to and those not related to
the study drug; Includes 1 subject who did not specify race.
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caused by AEs in subjects receiving tolterodine ER
vs. placebo (Table 2).
Dry mouth
Dry mouth was the most commonly reported AE
and the only AE consistently associated with toltero-
dine ER treatment (Figure 1A). Most instances of
tolterodine ER-related dry mouth were of mild to
moderate severity; the occurrence of severe dry
mouth was only 1% in each age category. There were
no treatment differences (v
2 = 2.5139; p = 0.285) in
the occurrence of dry mouth among subjects who
were aged < 65, 65–74 and ‡ 75 years (Figure 1A).
Constipation
The occurrence of constipation was < 5% in all
groups. Compared with placebo, there was a slightly
higher rate of constipation in subjects receiving tolte-
rodine ER treatment in each age cohort (Figure 1B).
However, this treatment effect did not differ signiﬁ-
cantly among the < 65-year, 65- to 74-year and
‡ 75-year age cohorts (v
2 = 0.3162; p = 0.854).
Headache
The occurrence of headache was generally low and
tended to decrease with age regardless of treatment.
Compared with the placebo group, headache was
reported by slightly more subjects receiving toltero-
dine ER in the < 65-year and 65- to 74-year cohorts
and by slightly fewer subjects in the ‡ 75-year cohort
(Figure 1C). However, there were no age-related
treatment differences (v
2 = 1.5548; p = 0.460) in the
occurrence of headache.
Nausea
The occurrence of nausea was low (< 2%) and
appeared to be slightly higher in the placebo group
and thus unrelated to tolterodine ER treatment. There
were no treatment differences in the occurrence of
nausea (v
2 = 0.1492; p = 0.928) among subjects aged
< 65 years, 65–74 years and ‡ 75 years (Figure 1D).
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Figure 1 Occurrence of dry mouth (A), constipation (B), headache (C), nausea (D), urinary tract infection (E), blurred
vision (F), dry eye (G), dizziness (H) and micturition disorder (I) by treatment and age group. TOL ER, tolterodine
extended release
Tolerability of tolterodine ER in older subjects 1201
ª 2009 The Authors
Journal compilation ª 2009 Blackwell Publishing Ltd Int J Clin Pract, August 2009, 63, 8, 1198–1204Urinary tract infection
Urinary tract infection did not appear to be related
either to age or to tolterodine ER treatment (Fig-
ure 1E). Overall, the occurrence of UTI was < 3%
in all age and treatment groups. There were no
age-related treatment differences (v
2 = 0.7097;
p = 0.701) in the rates of UTI.
Blurred vision
The occurrence of blurred vision was £ 1% in all of
the treatment and age cohorts; there were generally
no differences in the occurrence of blurred vision
between subjects receiving tolterodine ER and those
receiving placebo (Figure 1F). Furthermore, there
were no signiﬁcant treatment differences (v
2 =
1.2175; p = 0.544) in the occurrence of blurred
vision among subjects < 65 years, 65–74 years and
‡ 75 years.
Dry eye
The occurrence of dry eye was < 1% in all treatment
and age cohorts and appeared unrelated to toltero-
dine ER treatment (Figure 1G). There were no age-
related treatment differences (v
2 = 1.4730; p = 0.479)
in the rates of dry eye.
Dizziness
The occurrence of dizziness did not exceed 2% in
any treatment or age cohort (Figure 1H). There was
no evidence that the occurrence of dizziness was
associated with either age or tolterodine ER treat-
ment, and there were no treatment differences in the
occurrence of dizziness (v
2 = 1.8427; p = 0.398)
among subjects aged < 65 years, 65–74 years and
‡ 75 years.
Micturition disorder
Self-reported micturition disorder was experienced
by < 1% of subjects regardless of age or treatment
and was not associated with age or tolterodine ER
treatment (Figure 1I). The difference between treat-
ment groups in the rates of micturition disorder did
not vary by age (v
2 = 1.1182; p = 0.572).
Discussion
Although several studies have demonstrated that tol-
terodine ER is generally well tolerated in subjects
with different demographical characteristics
(23,26,27), none have investigated the tolerability of
tolterodine ER in subjects aged ‡ 75 years relative to
younger age groups. The current retrospective evalu-
ation of pooled data from ﬁve studies provides fur-
ther evidence that tolterodine ER is well tolerated in
younger (aged < 65 years) and in older subjects
(aged 65–74 or ‡ 75 years) with OAB. Importantly,
the ratio of discontinuations because of AEs between
tolterodine ER vs. placebo groups was similar among
subjects aged < 65 years and subjects aged 65–74 or
‡ 75 years. However, it was found that AE-related
discontinuation rates tended to be slightly higher in
older subjects in both treatment groups. This ﬁnding
is consistent with the notion that the older subjects
may be more prone to tolerability and safety issues
compared with their younger counterparts (32). Pos-
sible factors contributing to this ﬁnding may include
changes in pharmacokinetics of antimuscarinics with
age and polypharmacy in older patients (33). How-
ever, because the slight elevation in discontinuation
rates was of similar magnitude among subjects
‡ 75 years in both placebo and tolterodine ER treat-
ment groups, it is likely that this ﬁnding is primarily
attributable to other factors, perhaps including com-
orbidities that lead to study discontinuation.
Not surprisingly, dry mouth, the most commonly
reported AE associated with antimuscarinic agents
(29), was consistently higher in subjects treated with
tolterodine ER compared with placebo. Notably, nei-
ther the frequency nor the severity of dry mouth
associated with tolterodine ER treatment was greater
among subjects aged 65–74 or ‡ 75 years than
among subjects aged < 65 years. Headache and con-
stipation were also reported slightly more often by
subjects receiving tolterodine ER compared with pla-
cebo. The occurrence of the other AEs investigated,
including nausea, UTI, blurred vision, dry eye, dizzi-
ness and micturition disorder, was relatively low
(< 3%), and none appeared to be associated with or
attributed to tolterodine ER treatment. Moreover,
none of these AEs was higher in older subjects, and
no AEs occurred more frequently in subjects aged
65–74 or ‡ 75 years than among subjects aged
< 65 years who were treated with tolterodine ER.
These data should be viewed within the context of
their inherent limitations. For example, the analyses
did not take into account the potential differences in
medical comorbidities among the three age cohorts.
Furthermore, because these studies were not designed
for the purpose of comparing tolerability across age
groups, outcomes for which older people may be
particularly vulnerable were not assessed. The risk of
cognitive impairment, from mild confusion to delir-
ium and dementia, is of particular concern in older
patients with a variety of pharmacological agents,
including anticholinergic medications. Such concern
is based on age- and health-related changes in neuro-
pharmacological response and pharmacokinetics, as
well as increased total anticholinergic burden related
to greater likelihood of polypharmacy in the elderly
(34,35). One published study found that
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for mild cognitive impairment (MCI) among elderly
individuals (36); MCI was not evaluated in any of
the ﬁve studies included in the current analysis.
There is evidence that oxybutynin alters quantitative
electroencephalogram (qEEG) activity in healthy vol-
unteers (37) and may compromise cognitive activity
in older patients (38,39). Tolterodine does not read-
ily cross the blood–brain barrier (40) and exerts little
impact on qEEG activity (37), although there have
been isolated case reports of cognitive impairment
(41–43). This issue deserves further investigation
through large well-controlled clinical trials powered
to assess this outcome.
The data presented in this report are consistent
with the most recent Beers criteria (30), which pro-
vide guidance for appropriate prescribing practices in
older adults. The Beers criteria do not list tolterodine
as a medication to be avoided in older individuals
except in those with clinically signiﬁcant bladder out-
let obstruction (BOO). This is based on a theoretic
concern about increased risk of urinary retention
(30). As stated in the prescribing information for tol-
terodine ER and other antimuscarinics (44–48), such
agents must be used with caution in individuals of
any age with clinically signiﬁcant BOO. Thus, this
appears to be a class effect rather than an age-related
effect. Although not listed in the Beers criteria,
antimuscarinic agents are also contraindicated in
individuals with a history of unstable or untreated
narrow-angle glaucoma (44–48), the prevalence of
which is increased in older individuals.
These data are also consistent with previous studies
in which tolterodine immediate release (IR) was
shown to have a favourable tolerability proﬁle in older
subjects. In a double-blind placebo-controlled study
with subjects aged ‡ 65 years, no differences were
found in the occurrence of serious AEs between sub-
jects taking placebo vs. tolterodine IR (1 or 2 mg bid)
(26). Similarly, a logistic regression analysis of data
from a large, open-label, observational study did not
ﬁnd any signiﬁcant effect of age on the tolerability of
tolterodine IR treatment (27). The results of a nursing
home urinary incontinence management programme
also suggest that tolterodine IR (1 or 2 mg bid) is well
tolerated in this older population (28). The results of
the current analysis suggest that tolterodine ER, which
has better efﬁcacy and tolerability than tolterodine IR
(22), is also well tolerated in older individuals. This
ﬁnding, combined with the observations that toltero-
dine ER is an effective and safe treatment for OAB, is
important because the prevalence of OAB increases
with age. Thus, the potential for differential suscepti-
bility to these common AEs, as well as others, needs to
continue to be explored (3,4).
Conclusion
The results of the current analysis suggest that the
tolerability proﬁle of tolterodine ER is not dimin-
ished in older individuals (aged 65–74 years or
‡ 75 years) with OAB relative to younger individuals
(aged < 65 years). Moreover, there was no increase
in risk for commonly reported AEs in older vs.
younger subjects. This suggests that tolterodine ER is
suitable as a ﬁrst-line pharmacotherapy treatment for
OAB in older individuals.
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